Company Overview of N-of-One, Inc.
N-of-One, Inc., a molecular decision support company, provides clinicians with interpretation of molecular test results. It interprets molecular diagnostic test results and provides disease-specific biological relevance, clinical evidence, associated therapies, and references. The company interprets next generation sequencing (NGS) of solid and hematological tumors, circulating tumor cells and DNA, copy number analysis, and immunohistochemistry. In addition, it offers PrecisionInsights, a case-specific report for 15-20 gene NGS panels, delivering concise clinical and scientific evidence for each biomarker in the context of the cancer sub type and a list of therapeutic options; and TRIALMATCH...
430 Bedford Street
Lexington, MA 02420
Founded in 2007
Key Executives for N-of-One, Inc.
Chairman and Chief Executive Officer
Founder, President, Chief Medical Officer and Director
Chief Financial Officer and Director
Vice President of Operations
Vice President, Secretary and General Counsel
Compensation as of Fiscal Year 2015.
N-of-One, Inc. Key Developments
Wuxi Nextcode Selects N-of-One, Inc. for Global Relationship, to Provide Clinical and Scientific Evidence for Interpretation for Cancer
Nov 17 15
N-of-One, Inc. announced that it has signed a global agreement with WuXi NextCODE to provide clinical and scientific evidence for delivering the best personalized treatment options based on the results of WuXi NextCODE tumor-normal genome sequence interpretation, which identifies key driver mutations in individual tumors. WuXi NextCODE manages and interprets more genomes than any other system in the world. It is deploying its unique database, informatics and reporting system for major precision medicine efforts in the UK, US, China, Qatar and elsewhere in cancer, rare disease, and drug discovery and development. N-of-One clinical interpretation provides the relevant scientific and clinical evidence related to the mutation profile of a tumor identified by sequencing, taking into account each patient's specific molecular profile. This in turn links the clinical and scientific evidence to therapeutic strategies relevant for each patient. The global agreement between the companies enables them to collaborate on WuXi NextCODE’s work with the UK 100,000 Genomes Project and to tailor offerings for other geographies in the months ahead.
N-of-One Launches PrecisionInsights for Cost Effective, Quality Clinical Interpretation of 15-20 Gene NGS Solid Tumor Panels
Oct 6 15
N-of-One, Inc. announced N-of-One PrecisionInsights™, a new clinical interpretation solution specifically designed for small gene panels of 15-20 genes. N-of-One PrecisionInsights™ is a concise, two-page report for each case providing the most recent clinical and scientific evidence specific to the identified genes and variants in the context of the specific cancer sub type. Key attributes include: Turnaround time of one business day; Cost-effective pricing of $65 per report, with a one-time $1,000 implementation; Most up-to-date scientific and clinical evidence in the industry; and Incorporates NCCN guidelines and relevant therapies. As with other N-of-One clinical interpretation solutions, N-of-One PrecisionInsights™ is based on the same foundation of high-quality clinical interpretation: Case- and Disease-Specific: N-of-One interpretation is specific for each cancer subtype. For example, interpretation of a breast cancer case will address the impact of the detected somatic variants in the context of the specific histolopathology of the breast cancer. N-of-One Expertise and Experience: N-of-One’s team of over 30 on-staff PhD scientists and oncologists research and analyze each case to ensure accuracy and actionability. N-of-One’s knowledgebase is recognized as one of the most comprehensive sources of oncology clinical and scientific evidence in the industry.
Spectrum Health Selects N-of-One to Provide Clinical Interpretation for 50-Gene Hot-Spot Solid Tumor Panel
Aug 18 15
N-of-One, Inc. announced that it has signed an agreement with Spectrum Health to provide clinical interpretation for all cases sequenced on Spectrum Health’s 50-gene hot-spot solid tumor panel. The Spectrum Health Cancer Center is focused on delivering individualized care to each cancer patient. A commitment to high-quality care and innovation has made Spectrum Health a regional leader and a referral center for cancer treatment. N-of-One's clinical interpretation provides the relevant scientific and clinical evidence related to the mutation profile of a tumor identified by sequencing, taking into account each patient’s specific molecular profile. This in turn links the clinical and scientific evidence to therapeutic strategies relevant for each patient.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|